Safety of SARS-CoV-2 Vaccines: a Systematic Review and Meta-analysis of Randomized Controlled Trials
Overview
Affiliations
Background: Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for mass vaccination.
Main Text: A systematic review and meta-analysis was conducted to determine the safety of COVID-19 vaccine candidates in randomized controlled trials (RCTs). Data search was performed in PubMed, Embase, Cochrane library, Scopus, Web of Science, and MedRxiv. Included articles were limited to RCTs on COVID-19 vaccines. A total of 73,633 subjects from 14 articles were included to compare the risks of adverse events following immunization (AEFI) after vaccinating different COVID-19 vaccines. Pooled risk ratios (RR) of total AEFI for inactivated vaccine, viral-vectored vaccine, and mRNA vaccine were 1.34 [95% confidence interval (CI) 1.11-1.61, P < 0.001], 1.65 (95% CI 1.31-2.07, P < 0.001), and 2.01 (95% CI 1.78-2.26, P < 0.001), respectively. No significant differences on local and systemic AEFI were found between the first dose and second dose. In addition, people aged ≤ 55 years were at significantly higher risk of AEFI than people aged ≥ 56 years, with a pooled RR of 1.25 (95% CI 1.15-1.35, P < 0.001).
Conclusions: The safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported AEFI. Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.
Tavanaei Tamanaei T, Oghazian M, Mojtabaee M, Faregh M, Oghazian S, Tavana E Health Sci Rep. 2025; 8(3):e70492.
PMID: 40041786 PMC: 11872685. DOI: 10.1002/hsr2.70492.
Rajan A, Bashar M Ther Adv Vaccines Immunother. 2025; 13:25151355251321697.
PMID: 40034661 PMC: 11873861. DOI: 10.1177/25151355251321697.
Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review.
SeyedAlinaghi S, Pashaei A, Tantuoyir M, Karimi A, Mojdeganlou H, Nazarian N Tanaffos. 2025; 23(2):102-114.
PMID: 39959793 PMC: 11825072.
Domen J, Abrams S, Digregorio M, Van Ngoc P, Duysburgh E, Scholtes B BMC Infect Dis. 2024; 24(1):1135.
PMID: 39390398 PMC: 11468363. DOI: 10.1186/s12879-024-09969-8.
Beck E, Bausch-Jurken M, Van de Velde N, Wang X, Malmenas M Infect Dis Ther. 2024; 13(10):2195-2202.
PMID: 39180646 PMC: 11416437. DOI: 10.1007/s40121-024-01020-2.